Korro Bio, Inc. (KRRO) Stock Price, News, Quote & History
Korro Bio, Inc. (KRRO) is a biopharmaceutical company focused on developing genetic medicines based on RNA editing for various diseases. The company's stock is currently trading at $9.41, down 2.39%, with a 1-year target estimate of $20.20. Key financial data, performance overview, earnings trends, and analyst insights for KRRO are also presented.
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio has reported an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant involves options to purchase 45,000 shares of common stock, vesting over four years. This grant was approved by the company's Board of Directors and is a material inducement for the employee to join Korro Bio.
Formela Jean Francois Sells 48,690 Korro Bio Shares, Retains 132,650 Shares Post-Transaction
Formela Jean Francois sold 48,690 shares of Korro Bio (NASDAQ:KRRO) in four open-market transactions between September 11 and September 14, 2026, with prices ranging from $13.99 to $14.12 per share. Following these sales, her total holdings in the company are now 132,650 shares. The transactions were recorded under SEC code S, indicating open-market or private sales.
Senior finance VP at Korro Bio (KRRO) sells 7,353 shares under 10b5-1 trading plan
Oliver Dolan, Senior Vice President of Finance at Korro Bio (KRRO), sold 7,353 shares of common stock on September 8-9, 2026, through a Rule 10b5-1 trading plan. The sales were conducted at weighted-average prices of $13.5138 and $13.6033, respectively, totaling approximately $99,000. Dolan still retains 16,241 unvested RSU-based shares, with vesting scheduled through 2028.
Three new hires get options to buy 5,000 Korro Bio shares
Korro Bio (KRRO) has granted nonstatutory stock options for an aggregate of 5,000 shares to three new employees under its 2026 Inducement Plan. The options have an exercise price of $12.93 per share, a ten-year term, and vest over four years, with initial vesting on the first anniversary of employment. These grants, approved by Korro's Compensation Committee, serve as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company focused on genetic medicines, announced that its President & Chief Executive Officer, Ram Aiyar, will participate in upcoming investor conferences. The company leverages its OPERA® platform to develop treatments for rare and prevalent diseases. This announcement was distributed via GlobeNewswire.
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. (Nasdaq: KRRO) announced that its President & CEO, Ram Aiyar, will participate in two upcoming investor conferences. These include the Citi 2026 Biopharma Back to School Summit on September 9th, 2026, and the 2026 Cantor Global Healthcare Conference on September 10th, 2026. Korro will leverage these events to discuss its novel oligonucleotide promoted editing of RNA (OPERA®) platform for genetic medicines.
Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19
Korro Bio (KRRO) director Jean Francois Formela's associated venture funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 28,468 shares of common stock on August 19, 2026. The sales were executed at a weighted average price of $14.00 per share under a Rule 10b5-1 trading plan. Formela disclaims beneficial ownership except for any pecuniary interest in these indirect holdings.
Form 8K Korro Bio Inc For: 19 August By Investing.com
This article reports that Korro Bio Inc. filed a Form 8K on August 19, 2026. The filing is brief and does not contain additional details within the provided content. The stock symbol KRRO is noted as having increased by 3.43%.
Korro Bio (NASDAQ: KRRO) venture backer lines up more stock sales
Atlas Venture Opportunity Fund II, L.P. has filed a Form 144 to sell 4,884 shares of Korro Bio (KRRO) common stock through Merrill Lynch on Nasdaq. These shares were acquired in a private placement on April 22, 2024. The filing also reveals numerous other sales of Korro Bio shares by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P. over the past three months.
Korro Bio (KRRO) fund eyes new sale after $1.45M June trade
Atlas-affiliated funds have filed a Form 144 to sell 23,584 shares of Korro Bio (KRRO) common stock, valued at $311,780.48. This filing follows several significant sales by Atlas Venture Fund XI and Atlas Venture Opportunity Fund II in the past three months, including a June sale of over 100,000 shares for $1.45 million. The document provides details on proposed and prior sales, outstanding shares, and definitions of relevant SEC regulations.
Form 8K Korro Bio Inc For: 19 August By Investing.com
This article reports that Korro Bio Inc. filed a Form 8K on August 19. It also mentions the company's stock symbol KRRO, which saw a 5.52% increase. The piece is brief and does not include further details about the filing.
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock
Lynx1 Capital Management LP, a 10% owner of Korro Bio (NASDAQ:KRRO), purchased $78,809 worth of common stock in two transactions in early August 2026. These purchases were made at weighted average prices between $11.3998 and $13.1869 per share. The stock has seen significant year-to-date returns, and Korro Bio is advancing its treatment programs for hyperammonemia and alpha-1 antitrypsin deficiency.
Korro Bio director Jean Francois Formela sells $29,916 in shares
Korro Bio director Jean Francois Formela sold 2,143 shares of common stock for approximately $29,916 on August 11, 2026, under a pre-arranged trading plan. Despite the sale, his indirect beneficial ownership through Atlas Venture funds remains substantial. The stock has shown volatility and strong year-to-date returns, but InvestingPro analysis suggests it may be overvalued, while analysts maintain mixed ratings with price targets ranging from $15 to $23.
Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock
Korro Bio (NASDAQ:KRRO) director Jean Francois Formela sold 2,143 shares of the company's stock for $29,916.28 on August 11th, reducing his holdings by 1.45% to 145,937 shares. This sale is part of a pattern of recent insider selling by Formela, including significant transactions in June and July. Despite the insider selling, analysts maintain a "Moderate Buy" rating for Korro Bio with an average price target of $16.71.
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan
Korro Bio director Jean Francois Formela's affiliated funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 2,143 shares of Korro Bio common stock on August 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan adopted on April 8, 2026, occurred at a weighted average price of $13.96 per share. Formela disclaims full beneficial ownership, noting his pecuniary interest.
Korro Bio director Jean Francois Formela sells $29,916 in shares
Korro Bio director Jean Francois Formela sold 2,143 shares of the company's common stock for approximately $29,916 on August 11, 2026, under a Rule 10b5-1 trading plan. Despite recent volatility and a 67% year-to-date return, InvestingPro analysis suggests the stock may be overvalued. The company recently announced a new candidate for treating alpha-1 antitrypsin deficiency (AATD) and received reiterated Outperform ratings from Raymond James, while H.C. Wainwright adjusted its price target.
Lynx1 Capital Management Lp Buys 5,222 Shares of Korro Bio (NASDAQ:KRRO) Stock
Lynx1 Capital Management Lp increased its stake in Korro Bio (NASDAQ:KRRO) by purchasing 5,222 shares for $59,530.80 and an additional 1,462 shares later. This brings their total holdings to 1.54 million shares. Korro Bio reported better-than-expected quarterly results with a loss of $1.07 per share and revenue of $1.50 million, while analysts maintain a "Moderate Buy" rating with an average price target of $16.71.
Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock
Lynx1 Capital Management, a major shareholder in Korro Bio (NASDAQ:KRRO), recently acquired 1,462 shares for $19,283.78, increasing its stake to 1.54 million shares. This follows another purchase of 5,222 shares earlier in the month. Korro Bio's stock rose 1.8% to $13.59, and the company reported a smaller-than-expected quarterly loss and higher-than-anticipated revenue.
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock
Lynx1 Capital Management LP, a 10% owner of Korro Bio Inc. (NASDAQ:KRRO), purchased $78,809 worth of common stock through two transactions in early August 2026. These purchases increased Lynx1 Capital's indirect holdings to 1,544,980 shares. The company has also announced new pipeline additions and received reiterated analyst ratings, highlighting ongoing efforts in treating hyperammonemia and AATD.
Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase
Korro Bio, Inc. (KRRO) reported that insider Lynx1 Capital Management LP and Weston Nichols indirectly purchased a total of 6,684 shares of common stock. These purchases occurred on August 6, 2026, at a weighted average price of $11.3998 per share (5,222 shares), and on August 10, 2026, at a weighted average price of $13.1869 per share (1,462 shares). The entities disclaim beneficial ownership except to the extent of any pecuniary interest.
Korro Bio Inc (KRRO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Korro Bio Inc (KRRO) has an earnings forecast score of 8.20, ranking 159th in its industry, with an average analyst price target of $9.50. Analysts largely recommend a "Buy" for KRRO stock, with 11 analysts contributing to the rating. The company's expected revenue for the next quarter is $214.29K, and its previous quarter's EPS was -$1.69, with the next quarter's EPS projected at -$1.26.
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders
Korro Bio's stock recently climbed by 28%, adding US$42 million to its market value, much to the satisfaction of insiders who had purchased shares in the last year. Despite recent insider selling totaling US$439k, a significant insider purchase of US$2.3 million at a lower price earlier suggests confidence in the company's valuation. However, overall insider ownership remains relatively modest at 4.7%.
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders
Korro Bio's stock recently climbed 28%, adding US$42 million to its market value, much to the satisfaction of insiders who had purchased shares in the last 12 months. One insider, Mohamad Makhzoumi, bought US$2.3 million worth of shares at a lower price than the current market, suggesting he saw value. However, the company has seen significant insider selling in the last three months, totaling US$439k, with no recorded purchases, which could be a cause for caution despite earlier buying activity.
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders
Korro Bio (NASDAQ:KRRO) saw its market capitalization increase by US$42 million following a 28% stock climb, which benefited insiders who had purchased shares in the past year. While a significant insider purchase of US$2.3 million was made at a lower price, recent insider selling totaling US$439k indicates some caution. Insiders currently own 4.7% of the company, valued at US$9.1 million.
Korro Bio Refines Capital Structure with Exchange Agreement
Korro Bio has refined its capital structure through an exchange agreement with Venrock Healthcare Capital Partners, reducing outstanding common shares while issuing pre-funded warrants. The company also reported progress on its pipeline, including an Orphan Drug Designation for KRRO-121 and the nomination of KRRO-111 as a development candidate, with a solid cash position extending into the second half of 2028. Analysts maintain a "Buy" rating on KRRO stock with a $30.00 price target, despite TipRanks' AI Analyst giving it a "Neutral" score due to financial performance concerns.
Cantor Fitzgerald Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22
Cantor Fitzgerald has reiterated its Buy rating for Korro Bio (KRRO.US) and maintained its target price at $22. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Korro Bio (NASDAQ:KRRO) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Korro Bio (NASDAQ:KRRO) from "strong sell" to "sell," while the overall analyst consensus remains a "Moderate Buy" with a $16.71 price target. The company recently reported a quarterly loss of $1.07 per share, outperforming estimates, and revenue of $1.50 million, significantly above the consensus estimate. Despite positive earnings, insiders have sold approximately $4.31 million in shares over the past 90 days.
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders
Korro Bio, Inc. (NASDAQ:KRRO) saw a significant 28% stock climb last week, adding US$42 million to its market value, much to the benefit of insiders who purchased shares in the past year. While a large insider purchase was made at a lower price, there has been recent insider selling, making the overall insider sentiment a bit cautious. Insiders currently own 4.7% of the company, valued at US$9.1 million.
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook
Raymond James has reiterated an Outperform rating and a $23.00 price target for Korro Bio Inc., based on the company's expansion into hyperammonemia indications. Korro Bio plans to initiate the first human clinical study for its lead asset, KRRO-121, in the second half of 2026 and has nominated KRRO-111 for alpha-1 antitrypsin deficiency after demonstrating significant reduction of non-inclusion Z-AAT in mouse models. The company reported $137.9 million in cash and equivalents at the end of Q2 2026, sufficient to fund key value inflection points.
A Quick Look at Today's Ratings for Korro Bio(KRRO.US), With a Forecast Between $15 to $18
This article provides an overview of recent analyst ratings for Korro Bio (KRRO.US), showing a consensus analyst rating of "Buy" with an average price target of $16.50. The ratings are based on insights from three analysts, with individual price targets ranging from $15 to $18. This suggests a generally positive outlook for the company's stock from the analyst community.
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook
Raymond James has reiterated an Outperform rating and a $23.00 price target for Korro Bio Inc. (NASDAQ:KRRO), citing the company's expansion into hyperammonemia indications. Korro Bio expects to begin human clinical studies for its lead asset, KRRO-121, in late 2026, and also advanced KRRO-111 for alpha-1 antitrypsin deficiency. The company ended Q2 2026 with $137.9 million in cash, which it states is sufficient to fund key development milestones.
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15
Chardan Capital has reiterated its Buy rating on Korro Bio (KRRO.US) and maintained its target price of $15. This indicates continued confidence from the firm in the biotechnology company's potential.
Korro Bio, Inc. Q2 2026: Revenue $0M, Net loss $(18.9)M, EPS $(1.07) — 10-Q Summary
Korro Bio, Inc. reported no revenue for Q2 2026 due to a paused collaboration with Novo Nordisk, resulting in a net loss of $(18.9)M and diluted EPS of $(1.07). The company saw an improvement in net loss compared to the previous year, reallocated resources to prioritize KRRO-111 and KRRO-121, and extended its cash runway into the second half of 2028 through recent financings.
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio, Inc. announced its second-quarter 2026 financial results, highlighting key advancements in its RNA editing programs. The company reported $137.9 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. Key developments include receiving Orphan Drug Designation for KRRO-121 for urea cycle disorders and nominating KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency.
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in its RNA editing programs. The company ended the quarter with $137.9 million in cash, which is expected to fund operations into the second half of 2028. Key milestones include receiving Orphan Drug Designation for KRRO-121, nominating KRRO-111 as a development candidate for AATD, and advancing preparations for clinical trials for KRRO-121.
Korro Bio Swaps 1.0M Shares for Pre-Funded Warrants to Venrock at $0.001 Exercise Price
Korro Bio (KRRO) entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026. Venrock surrendered 1,000,000 Korro shares, and in return, Korro issued pre-funded warrants to purchase 1,000,000 shares at a $0.001 exercise price. These warrants have no expiration, are immediately exercisable, and are subject to a 9.99% beneficial ownership cap. Following this exchange, Korro Bio reported 13,725,646 shares outstanding and unexercised pre-funded warrants for 4,148,836 shares.
Korro Bio (KRRO) CEO sells 5,802 shares of stock to cover taxes
Korro Bio's President and CEO, Ram Aiyar, sold 5,802 shares of common stock on August 4, 2026, at a weighted-average price of $10.844 per share. This sale was mandatory to cover tax withholding obligations on vested Restricted Stock Units (RSUs) under the company's 2023 Stock Option and Incentive Plan. Following this transaction, Aiyar directly holds 69,046 shares, including 20,000 unvested RSUs, and indirectly holds 4,613 shares through a trust.
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of "Moderate Buy" from Analysts
Korro Bio, Inc. (NASDAQ:KRRO) has received a consensus "Moderate Buy" rating from twelve research firms, with an average 12-month price target of $16.71. Despite insider selling totaling approximately $4.31 million and recent quarterly EPS missing estimates, institutional investors have increased their positions in the clinical-stage biotechnology company. Korro Bio, which develops enzyme therapies and microbial therapeutics, opened at $10.37, below its average analyst price target.
Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Korro Bio Inc (KRRO), detailing its current price momentum score, support and resistance levels, and indicator readings. It also includes an analysis of various technical indicators like MACD, RSI, and moving averages, offering buy/sell signals for each. The analysis suggests a range-bound swing trading opportunity for KRRO, with mixed signals from different indicators.
Korro Bio Inc (KRRO) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Korro Bio Inc (KRRO), highlighting its current valuation score of 6.82, which ranks it 287 out of 384 in the Biotechnology & Medical Research industry. It notes that the company's P/E ratio is -0.86, being significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
KRRO|Korro Bio Inc|Price:10.060|Chg%:-0.440
Korro Bio Inc. (KRRO) has a TradingKey Stock Score of 5.93/10, indicating stable fundamentals and significant growth potential, although its valuation is considered fair at 129th out of 384 in its industry. Analysts have largely rated the stock a "Buy" with a target price of $19.556, suggesting an 82.42% upside. However, the stock has shown weak market performance recently and is trading sideways, making it suitable for range-bound swing trading according to the analysis.
Korro Bio Inc (KRRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Korro Bio Inc (KRRO), detailing its business segments, regional revenue, and profit contribution. It notes that relevant data for fiscal years 2024 and 2025 (including quarterly data) has not yet been disclosed by the company, though it lists United States revenue at $6.39 million. The report also includes current stock information for KRRO.
KRRO|Korro Bio Inc|Price:10.640|Chg%:-0.890
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing genetic medicines by editing RNA. Their lead candidate, KRRO-110, targets Alpha-1 Antitrypsin Deficiency (AATD). The article provides company details, financial data, executive information, and institutional shareholding statistics for KRRO.
Korro Bio, Inc. Revenue Breakdown – NASDAQ:KRRO
Korro Bio, Inc. (NASDAQ: KRRO) generated $6.40 million USD in revenue last year. The majority of this revenue, $6.39 million USD, came from its RNA-editing Technology segment, significantly up from $2.27 million USD the previous year. The United States was the primary contributor, accounting for $6.39 million USD of the revenue.
Korro Bio Inc (KRRO) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Korro Bio Inc (KRRO). It notes that the company has distributed $0.00 in dividends over the past five years and lists several merger-related stock splits that occurred on November 3, 2023. The stock information includes its current price, market cap, and P/E TTM.
Korro Bio Inc (KRRO) Cash Flow
The article provides a detailed cash flow statement for Korro Bio Inc (KRRO), including quarterly and annual data for operating, investing, and financing cash flows. It also defines key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow, explaining their significance for evaluating a company's financial health. The data shows Korro Bio Inc's specific cash flow figures and year-over-year changes, highlighting its performance in these areas.
Korro Bio Inc (KRRO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Korro Bio Inc (KRRO) has an earnings forecast score of 8.20, ranking 154th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.50 for KRRO, with a significant upside potential of 69.61%. The consensus among 10 analysts is a "Buy" rating for the stock.
KRRO|Korro Bio Inc|Price:10.640|Chg%:-0.890
Korro Bio Inc. (KRRO) is a clinical-stage biopharmaceutical company focused on RNA editing. The stock is currently trading at $10.640, down 7.72% for the day. Analysts have a "Buy" rating with a target price of $19.556, despite the stock showing weak market performance over the past month.
Korro Bio (KRRO) awards SVP 5,500 RSUs vesting through 2028
Korro Bio, Inc. (KRRO) Senior Vice President, Finance, Oliver Dolan, was granted 5,500 restricted stock units (RSUs) on July 15, 2026. These RSUs will vest in two tranches: 50% on July 15, 2027, and 50% on July 15, 2028, contingent on his continuous employment. Following this award, Dolan directly holds 23,599 shares, including 16,241 unvested RSU shares.
